“global Single Lead ECG Equipment Market is anticipated to surpass USD 450 Million by 2020”, says Visiongain

07 November 2019
Pharma

Visiongain has launched a new pharma report “Single Lead ECG Equipment Market Report 2020-2030” Prospects by Indication {Syncope, Arrhythmia (Atrial Fibrillation, Bradycardia, Tachycardia), Other Indications}, End users {Hospitals & Clinics, Home-care, Ambulatory Surgical Centers (ASCs)}, and Geography.

Global Single Lead ECG Equipment market is projected to grow on account of high prevalence of atrial fibrillation, advent of technology with respect to mobile ECG, and government regulations in the favor of remote monitoring devices among other contributing growth factors. The global market is projected to grow at a lucrative CAGR of ~5% over the forecast period from 2020 to 2030 and is anticipated to surpass USD 450 Million by 2020.

An ECG or electrocardiogram is a record of the heart's electrical activity. There are different types of ECG, but the most widely used is the single-lead ECG. By using ECG, it is possible to assess multiple heart problems and anomalies. This lets the doctor determine the patient's appropriate treatment.

The growing factors such as the increased prevalence of chronic as well as cardiovascular disease, increasing geriatric population, adoption of advanced technology, knowledge of cardiovascular disease and others, the single-lead ECG equipment market is anticipated to grow during the forecast period.

With the growing popularity of home care, these applications are capable of gaining significant traction in the foreseeable future due to a shift in direction towards personalized health monitoring solutions. Also, changing cardiac assessment preferences to self-triage before selecting complicated analytical systems contribute to the advent of single-lead ECG smartphone and mobile-based monitoring, thereby driving the market.

However, some entities combine mobile interoperability with ECG monitoring devices to provide users with immediate and easy access to ECG waveforms. These activities allow patients to experience improvement in the treatment of cardiovascular disease. Such advances in technology are likely to boost market growth over the forecast period.

To attract consumers and keep them interested along with consequent acceptance, market participants are engaged in developing an innovative product. Issues faced include the need for information management systems so that findings and evaluation can be communicated directly with physicians. Nonetheless, customer centricity-based programs are expected to reduce the effects of such challenges.

Due to ongoing developments in-home and outpatient health care in the region, North America dominated the global lead ECG equipment market in 2018. Moreover, due to the increased incidence of cardiovascular diseases, this region is experiencing a high mortality rate, which in turn increases the demand for such home-use technology in the coming years.

On the other hand, during the forecast period, Asia Pacific is likely to witness the fastest growth. Emerging economies, wearable devices' growing popularity, continuously evolving infrastructure, and presence of target population are among the local market's primary growth stimulus.

Markets in developing economies such as India are growing to build healthcare infrastructure and provide advanced primary healthcare services through partnerships with the government. Increasing consumer inclination towards mobile phone connected devices is also anticipated to fuel market growth over the forecast period.

Some of the major players operating in this industry are AliveCor, Inc., Ambisea Technology Corp. Ltd., CONTEC MEDICAL SYSTEMS CO. LTD., DailyCare BioMedical, Inc., Dimetek Digital Medical Technologies, Ltd., DRE Medical, Inc., Eurocamina Lohman Technologies, Lohman Technologies, Longfian Scitech Co.Ltd, OMRON Corporation, Perlong Medical Equipment Co., Ltd, REKA Health Pte Ltd, Shenzhen Creative Industry Co., Ltd, SUZUKEN CO. LTD., Tianjin Chase Sun Pharmaceutical Group, VCOMIN TECHNOLOGY LIMITED, Zenicor Medical Systems, Qardio, Inc., Tianjin Chase Sun Pharmaceutical Group, Eurocamina among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

Read

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

Read

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

Read

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever